Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
10 10 2019
Historique:
received: 07 07 2019
accepted: 25 09 2019
entrez: 11 10 2019
pubmed: 11 10 2019
medline: 14 8 2020
Statut: epublish

Résumé

Pemetrexed combined with platinum complexes can be used as first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC), however, the efficacy and safety is varying from individuals. There is a need to better understand the genetic variations associated with platinum response. We performed next-generation sequencing (NGS) based on BGI Oseq-ctDNA panel to analyze 98 longitudinal plasma samples from 32 lung adenocarcinoma patients during platinum-based chemotherapy, and a bioinformatic pipeline was developed to detect point mutations. We found that mutation burden was decreased after chemotherapy, which reflected chemotherapy sensitivity, especially the frequency of C>G and C>A substitutions. Moreover, neoplastic cells carrying a specific set of somatic mutations, such as EGFR(L858R), KRAS (p.G12C) were obviously correlated with platinum treatment. In addition, the MAPK pathway was found to have a pivotal role in NSCLC and platinum based response. Finally, we found that smokers benefit less from platinum-based chemotherapy. Collectively, this work described the dynamic changes of ctDNA mutation status during platinum-based treatment, which may contribute to advanced lung adenocarcinoma patients stratification and precision treatment.

Identifiants

pubmed: 31597567
doi: 10.1186/s12967-019-2087-9
pii: 10.1186/s12967-019-2087-9
pmc: PMC6785899
doi:

Substances chimiques

Circulating Tumor DNA 0
Platinum 49DFR088MY

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

339

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Thorac Oncol. 2015 May;10(5):768-777
pubmed: 25738220
Curr Pharm Des. 2013;19(5):883-94
pubmed: 22973957
J Thorac Cardiovasc Surg. 2008 May;135(5):1036-41
pubmed: 18455581
Eur Respir J. 2015 Dec;46(6):1773-80
pubmed: 26493785
Am J Med Genet C Semin Med Genet. 2013 May;163C(2):86-91
pubmed: 23592277
Trends Genet. 2016 Jun;32(6):360-371
pubmed: 27129983
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Clin Chem. 2013 Jan;59(1):211-24
pubmed: 23065472
Nat Med. 2014 Jun;20(6):682-8
pubmed: 24836576
Mol Oncol. 2014 May;8(3):555-64
pubmed: 24495481
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Am J Respir Crit Care Med. 2017 May 1;195(9):1150-1160
pubmed: 28459327
Cancer Res. 2018 May 1;78(9):2179-2190
pubmed: 29490947
Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253
pubmed: 29504834
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Pathology. 2013 Dec;45(7):645-50
pubmed: 24247621
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Clin Cancer Res. 2017 Sep 1;23(17):5101-5111
pubmed: 28539465
Nat Genet. 2017 Jan 31;49(2):170-174
pubmed: 28138153
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21083-8
pubmed: 24324171
Nat Commun. 2017 May 26;8:15290
pubmed: 28548104
Genet Med. 2009 Jan;11(1):3-14
pubmed: 18813139
Chin J Cancer. 2015 Jan;34(1):4-16
pubmed: 25556614
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Gastrointest Oncol. 2017 Oct;8(5):858-866
pubmed: 29184690
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Springerplus. 2016 Apr 26;5:531
pubmed: 27186495
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Commun. 2015 Nov 26;6:8806
pubmed: 26608094
Ann Oncol. 2014 Sep;25(9):1729-35
pubmed: 25009010
J Clin Oncol. 2009 Feb 20;27(6):986-93
pubmed: 19075281
Sci Transl Med. 2017 Aug 16;9(403):null
pubmed: 28814544
Cancer. 2014 Nov 15;120(22):3446-56
pubmed: 24948110
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
PLoS One. 2011;6(11):e27792
pubmed: 22132142
Nat Med. 2015 May;21(5):483-91
pubmed: 25894826
Clin Cancer Res. 2016 Dec 1;22(23):5772-5782
pubmed: 27601595
J Clin Oncol. 2007 Nov 20;25(33):5240-7
pubmed: 18024870

Auteurs

Xiaohong Han (X)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Ying Han (Y)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Qiaoyun Tan (Q)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Yu Huang (Y)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Jianliang Yang (J)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Sheng Yang (S)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Xiaohui He (X)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Shengyu Zhou (S)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Yan Song (Y)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Jinping Pi (J)

Beijing Chaoyang Sanhuan Cancer Hospital, Beijing, China.

Lijie Zuo (L)

Beijing Chaoyang Sanhuan Cancer Hospital, Beijing, China.

Jiarui Yao (J)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Di Wu (D)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Zhishang Zhang (Z)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Yuankai Shi (Y)

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. syuankaipumc@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH